Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.(1) Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Bilal A., Subudhi, Sumit K., Sharma, Padmanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044095/
https://www.ncbi.nlm.nih.gov/pubmed/35492243
http://dx.doi.org/10.1016/j.xcrm.2022.100613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044095/
https://www.ncbi.nlm.nih.gov/pubmed/35492243
http://dx.doi.org/10.1016/j.xcrm.2022.100613

Ejemplares similares